Neuramis Deep (with Lidocaine)

Neuramis

Aesthetic / Medical Device

Hyaluronic Acid Dermal Filler (Deep volumising / wrinkle correction)

CE marked (manufacturer/distributor claims for Neuramis series in EU/EEA markets).
Manufactured in facilities claiming compliance with regional regulatory standards and quality controls (manufacturer: Medytox).
Hyaluronic acid raw material registered in DMF/EDQM or equivalent per manufacturer/distributor statements (verify local regulatory documentation).

CE marked (manufacturer/distributor claims for Neuramis series in EU/EEA markets).
Manufactured in facilities claiming compliance with regional regulatory standards and quality controls (manufacturer: Medytox).
Hyaluronic acid raw material registered in DMF/EDQM or equivalent per manufacturer/distributor statements (verify local regulatory documentation).

Hyaluronic Acid Dermal Filler (Deep volumising / wrinkle correction)

Description

Neuramis Deep with Lidocaine is a stabilized, cross-linked hyaluronic acid (HA) dermal filler formulated for correction of moderate-to-deep facial wrinkles and for volume augmentation of cheeks, chin and lips. The product contains HA at 20 mg/mL and includes lidocaine (0.3%) in the gel to improve injection comfort. It is supplied as single-use prefilled 1 mL syringes and is intended for intradermal/subcutaneous injection by trained medical professionals.

Bnefits

High HA concentration (20 mg/mL) for deeper volume replacement and correction of folds.
Includes lidocaine (0.3%) for reduced injection pain and improved patient comfort.
SHAPE™ two-step cross-linking and purification process (manufacturer claim) for gel stability and long-lasting effect.
Designed for natural-looking correction of nasolabial folds, marionette lines, cheek/chin augmentation and lip contouring.
Low residual BDDE levels per manufacturer quality specifications.

Indications

Correction of moderate-to-severe facial wrinkles and folds (e.g., nasolabial folds).
Volume augmentation (cheeks, chin, jawline) and lip enhancement where a deeper filler is indicated.
Use by qualified medical practitioners for aesthetic facial procedures.

Composition

Hyaluronic acid (cross-linked) — 20 mg/mL (2.0% w/v)
Lidocaine (as hydrochloride) — 0.3% w/w (which corresponds to approximately 3 mg/mL)
Crosslinking agent residuals present at levels compliant with manufacturer quality controls (BDDE residuals reported as very low by manufacturer)
Excipients and sterile water for injection (complete INCI/IFU available in manufacturer documentation)

Formulation

Not publicly listed

Packaging

Not publicly listed

Usage

Intended for administration by trained medical professionals experienced in dermal filler injections.
Follow aseptic technique and local injection protocols (depth, volume and technique per treatment area).
Use standard pre- and post-injection precautions (patient history, allergy check, informed consent).
Have hyaluronidase available for potential adverse events requiring filler dissolution.

Contraindications

Active infection or inflammation at the injection site.
Known hypersensitivity to any component of the product (including lidocaine or HA).
Patients with severe allergies, history of anaphylaxis, or sensitivity to gram-positive bacterial proteins used in HA production (if applicable).
Not indicated for use in areas with thin skin where deep fillers are inappropriate, unless clinician deems suitable.

Adverse Effects

Common, usually transient: swelling, redness, pain/tenderness, bruising, itching at injection site.
Less common but serious: infection, vascular occlusion, granuloma formation, nodules, hypersensitivity/allergic reactions.
Lidocaine-related adverse effects possible in rare systemic exposure (dizziness, allergic reaction) — typically minimal with correct administration.

Storage Conditions

Store in original packaging at controlled room temperature as specified in the product IFU (avoid freezing and excessive heat).
Protect from direct sunlight and keep out of reach of children.